Boehringer Ingelheim Starts Phase III Registration For Hepatitis C Drug
This article was originally published in PharmAsia News
Boehringer Ingelheim has started Phase 3 registration for its interferon-free triple drug polymodal therapy using protease inhibitor faldaprevir (BI 201335 NA), non-nucleoside polymerase inhibitor “BI 207127 NA”, and oral drug ribavirin for the treatment of Hepatitis C.
You may also be interested in...
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While its basic science is plausible, its best-in-class claims are bound to generate skepticism.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.